Preclinical biodistribution and safety evaluation of human iPSC-derived dopaminergic neural progenitor cells for Parkinson's disease.
Saved in:
| Title: | Preclinical biodistribution and safety evaluation of human iPSC-derived dopaminergic neural progenitor cells for Parkinson's disease. |
|---|---|
| Authors: | Huang Y; Institute of Safety Evaluation, National Institutes for Food and Drug Control, Beijing, China.; Beijing Key Laboratory of Quality Control and Nonclinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products, Beijing, China., Wen H; Institute of Safety Evaluation, National Institutes for Food and Drug Control, Beijing, China.; Beijing Key Laboratory of Quality Control and Nonclinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products, Beijing, China., Li L; XellSmart Biopharmaceutical (Suzhou) Co., Ltd, Suzhou, China., Li L; Institute of Safety Evaluation, National Institutes for Food and Drug Control, Beijing, China.; Beijing Key Laboratory of Quality Control and Nonclinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products, Beijing, China., Li Q; Institute of Safety Evaluation, National Institutes for Food and Drug Control, Beijing, China.; Beijing Key Laboratory of Quality Control and Nonclinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products, Beijing, China., Qin C; Institute of Safety Evaluation, National Institutes for Food and Drug Control, Beijing, China.; Beijing Key Laboratory of Quality Control and Nonclinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products, Beijing, China., Mao Y; Institute of Safety Evaluation, National Institutes for Food and Drug Control, Beijing, China.; Beijing Key Laboratory of Quality Control and Nonclinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products, Beijing, China., Lin Z; Institute of Safety Evaluation, National Institutes for Food and Drug Control, Beijing, China.; Beijing Key Laboratory of Quality Control and Nonclinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products, Beijing, China., Jiang H; Institute of Safety Evaluation, National Institutes for Food and Drug Control, Beijing, China.; Beijing Key Laboratory of Quality Control and Nonclinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products, Beijing, China., Zhu F; XellSmart Biopharmaceutical (Suzhou) Co., Ltd, Suzhou, China., Li X; XellSmart Biopharmaceutical (Suzhou) Co., Ltd, Suzhou, China., Geng X; Institute of Safety Evaluation, National Institutes for Food and Drug Control, Beijing, China.; Beijing Key Laboratory of Quality Control and Nonclinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products, Beijing, China. |
| Source: | Frontiers in cell and developmental biology [Front Cell Dev Biol] 2026 Jan 02; Vol. 13, pp. 1701748. Date of Electronic Publication: 2026 Jan 02 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101630250 Publication Model: eCollection Cited Medium: Print ISSN: 2296-634X (Print) Linking ISSN: 2296634X NLM ISO Abbreviation: Front Cell Dev Biol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2296-634X |
|---|---|
| DOI: | 10.3389/fcell.2025.1701748 |
